HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neutrogena T-Gel use with Merck's Propecia baldness drug recommended -- FDA cmte.

This article was originally published in The Rose Sheet

Executive Summary

NEUTROGENA T-GEL/MERCK PROPECIA CONCOMITANT USE RECOMMENDED FOR BALDNESS treatment by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee during the group's Nov. 13 review of the prescription oral hair regrowth drug finasteride. FDA had asked the committee to consider the effect of Neutrogena's OTC coal tar dandruff shampoo "on the assessment of the treatment response to Propecia." T-Gel was used in both the treatment and control groups of Merck's safety and efficacy trial for Propecia as a prophylaxis for seborrheic dermatitis. The recommended dose of T-Gel used during the trial was not specified.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel